Eyepoint Pharmaceuticals, INC Form 4 insider transactions

EyePoint Pharmaceuticals Director Nancy Lurker acquired 11,111 shares of common stock on July 10, 2025, through the vesting of restricted stock units, increasing her direct beneficial ownership.

EyePoint Pharmaceuticals CEO Jay S. Duker reported the vesting of restricted stock units and subsequent tax-related share dispositions on July 10, 2025.

EyePoint Pharmaceuticals Director Nancy Lurker transferred 232,021 vested stock options with various exercise prices to an irrevocable family trust on July 2, 2025, for estate planning purposes.

EyePoint Pharmaceuticals, Inc. President and CEO Jay S. Duker has disclosed the transfer of 56,665 shares of common stock to a family trust as part of a pre-planned transaction.

EyePoint Pharmaceuticals' Chief Financial Officer, George Elston, reported the vesting of 7,500 restricted stock units and the subsequent withholding of 2,202 shares for tax obligations.

Director Karen L. Zaderej reports purchasing 10,000 shares of EyePoint Pharmaceuticals (EYPT) common stock in two transactions on May 16 and May 19, 2025.

Director Karen L. Zaderej increased her holdings in EyePoint Pharmaceuticals through open market purchases on May 14 and 15, 2025.

Jay S. Duker, CEO of EyePoint Pharmaceuticals, sold 20,000 shares to a family trust at $6.155 per share and disclaims beneficial ownership of shares held by the trust.

George Elston, CFO of EyePoint Pharmaceuticals, reports the acquisition of 5,834 shares of common stock and the disposition of 5,834 restricted stock units on February 9, 2025.

Director Nancy Lurker reports the vesting of restricted stock units and subsequent acquisition of common stock, along with holdings in a family trust.

Jay Duker, President and CEO of EyePoint Pharmaceuticals, reports the vesting of restricted stock units and subsequent transactions involving common stock.

Director Reginald J. Sanders of EyePoint Pharmaceuticals acquired 80,000 stock options on January 8, 2025, exercisable in installments starting January 8, 2026.

Director Fred Hassan reports acquisition of 40,000 EyePoint Pharmaceuticals stock options on January 3, 2025.

Director Karen L. Zaderej acquired 40,000 stock options in EyePoint Pharmaceuticals on January 3, 2025.

Director Goran Ando acquired 41,500 stock options in EyePoint Pharmaceuticals on January 3, 2025.

Director Stuart Duty acquired 40,000 stock options in EyePoint Pharmaceuticals on January 3, 2025.

Director Wendy F. Dicicco reports the acquisition of stock options in EyePoint Pharmaceuticals.

Chief Medical Officer Ramiro Ribeiro of EyePoint Pharmaceuticals reports the acquisition of restricted stock units and stock options.

Chief Financial Officer of EyePoint Pharmaceuticals, George Elston, reports acquisition and disposal of common stock and derivative securities.

Director Nancy Lurker reports acquisition and disposal of EyePoint Pharmaceuticals stock and derivative securities.

Director John B. Landis of EyePoint Pharmaceuticals reports the acquisition of stock options and vesting of restricted stock units.

EyePoint Pharmaceuticals' CEO, Jay Duker, reports the acquisition and disposal of common stock and derivative securities, including restricted stock units and stock options, primarily related to vesting and tax obligations.

Director Fred Hassan of EyePoint Pharmaceuticals acquired 60,000 stock options on September 3, 2024, exercisable in installments starting September 3, 2025.

Director Wendy Dicicco of EyePoint Pharmaceuticals reports purchasing 2,567 shares of common stock at an average price of $7.79.

Director Goran Ando of EyePoint Pharmaceuticals, Inc. purchased 5,000 shares of common stock at $7.95 per share on August 21, 2024.

Director Karen L. Zaderej of EyePoint Pharmaceuticals, Inc. purchased 12,500 shares of common stock at an average price of $7.98 on August 19, 2024.

Director Nancy Lurker of EyePoint Pharmaceuticals, Inc. purchased 3,173 shares of common stock at an average price of $7.88 on August 16, 2024.

Director Nancy Lurker transferred vested stock options to an irrevocable family trust on July 26, 2024.

Director David R. Guyer exercised stock options and sold shares of EyePoint Pharmaceuticals on July 12, 2024.

EyePoint Pharmaceuticals' CEO, Jay Duker, reports acquisition and disposal of company stock and restricted stock units.